-

Shareholder Alert: Robbins LLP Announces It Is Investigating Sorrento Therapeutics, Inc. (SRNE) for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Sorrento Therapeutics, Inc. (NASDAQ: SRNE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Sorrento is a clinical stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.

If you suffered a loss as a result of Sorrento's misconduct, click here.

Sorrento Therapeutics, Inc. (SRNE) Accused of Misleading Investors

On May 15, 2020, Sorrento announced that it had discovered an antibody that had "demonstrated 100% inhibition of SARS-CoV-2 virus infection" and stated on national television "[Sorrento] want[s] to emphasize there is a cure." Following these auspicious statements, Sorrento's stock price soared to as high as $10.00 per share, representing a 281.7% increase from its May, 14, 2020 closing price. However, on May 20, 2020, Hindenburg Research issued a report calling Sorrento's claims "sensational," "nonsense," and "too good to be true" after speaking with Mount Sinai, the company Sorrento was collaborating with, which cautioned that "nothing in medicine is 100%." Finally, on May 22, 2020, BioSpace published an article revealing that in an interview on May 21, 2020, Sorrento's officers "insist[ed] that they did not say it was a cure" but rather that it could potentially be a cure. On this news, Sorrento's stock price fell to $4.93 per share, representing a 49.4% decline from its class period high of $10 per share.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Sorrento settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:SRNE
Release Versions
English
$Cashtags
$SRNE
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

LKQ Corporation Class Action Reminder - Robbins LLP Encourages LKQ Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired LKQ Corporation (NASDAQ: LKQ) common stock between February 27, 2023 and July 23, 2025. LKQ is a global distributor of alternative collision replacement parts, recycled engines, and other vehicle components for the repair of automobiles.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.Wha...

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...
Back to Newsroom